Revance Therapeutics (NASDAQ:RVNC) has filed a marketing application
in the U.S. seeking approval of DAXI (daxibotulinumtoxinA for
injection) for the treatment of moderate-to-severe glabellar (frown)
lines. The agency’s action date is November 25.
Share up 3% premarket on light volume.
Related tickers: Allergan (NYSE:AGN), Nestle S.A. (OTCPK:NSRGY), Evolus (NASDAQ:EOLS), Ipsen (OTCPK:IPSEY)
https://seekingalpha.com/news/3539211-revance-files-u-s-application-for-frown-line-treatment-shares-up-3-premarket
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.